Apolipoprotein E (apo E), a major apolipoprotein in the brain, was detected for the first time in cerebrospinal fluid (CSF) 15 years ago.' Apart from its role in plasma cholesterol homeostasis, apo E is thought to participate in the mobilization and redistribution of lipids during normal development of the nervous system and in the regeneration of peripheral nerves after injury.2,3 Two previous studies on CSF apo E in multiple sclerosis (MS) reported variable results.t-' We have evaluated the intrathecal synthesis of apo E in MS using a highly sensitive time-resolved irnmunofluorometric assay (TR-IFMA) developed in our laboratory.
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MATERIALS AND METHODS
Matched pairs of sera and CSF were obtained from the following patients and controls free of immunological abnormalities and dyslipoproteinaemia: 10 control subjects (7 men and 3 women; age 25-75 years) without neurological or psychiatric symptoms; 29 definite MS patients, diagnosed according to Poser's criteria: (6 men and 23 women, age: 17-68 years); 24 patients (15 men and 9 women, age: 29-79 years) with other neurological diseases (OND). MS patients were not on any treatment at the time of study. Goat anti-human apo E IgG (a gift from Professor Baudner, Behring Institute, Marburg, Germany) isolated with protein G (Hi-TrapTM, Pharmacia, Uppsala, Sweden) and shown to react with the three major isoforms of apo E (apo E2, apo E3 and apo E4) was labelled by incubation with europium (Pharmacia) as described for apo B. 6 Unlabelled anti-human apo E IgG (50 JoLg/mL) 148 was used for coating the microtitre plates, (Microwell'P", Nunc Inc, Napaville, CA, USA). The wells were then washed three times with 250 JoLL of a solution containing 50 mmol/L NaH 2P04 , 60 g of sorbitol and O' 5 giL of bovine serum albumin to block non-specific binding sites. Reference standard apoproteins human (Immuno AG, Vienna, Austria), which has an apo E concentration of 48 mg/L, was diluted to prepare the standard curve. Serum and CSF samples were diluted 10-4 and 10-2, respectively, and incubated. The wells were washed, and then incubated with the conjugate (europium-labelled anti-apo E antibody solution). After washing, enhancement solution was added and the fluorescence was measured as counts per second in a time-resolved fluorometer Arcus™1230 (Wallac, Turku, Finland).
As apolipoprotein B (apo B) binds to low density-lipoprotein receptors (B, E receptors) which are present on glial cells, including oligodendrocytes, apo B was also measured in serum and CSF by a TR-IFMA as described previously." The blood/CSF ratio and an index analogous to the CSF IgG index were calculated for apo E and apo B as previously reported for lipoprotein (a):? to its relative molecular mass (apo B = 549 000, apo E = 33 000) comparatively to albumin transudation; 210 mg/L is the mean reference value of CSF albumin.
RESULTS AND DISCUSSION
The TR-IFMA assay for apo E was linear between 24 /Lg/Land 4800 /Lg/L and had a detection limit of 10 /Lg/L. The within-run (n = 15)coefficients of variation (CVs) were 11· 6% at 24/Lg/L, 8·20/0 at 48/Lg/L and 11·3% at 240/Lg/L apoE. The between-run (n = 11) CVs were 11·6% at 48 /Lg/L and 7· 8% at 120/Lg/L apo E. Serum apo E concentration was significantly higher (P<O'OI) in MS patients than in controls and OND patients (Table 1) . In contrast, CSF apo E concentration was significantly lower (P<O·OI) in the MS group compared to the other groups and ITS of apo E was significantly lower (P<O·OOI). The apoE blood/CSF ratio was higher (P<O·OOI) in the MS group than in the other groups. Regardless of the patient group considered, there was no correlation between serum and CSF apo E concentration or between serum apo E concentration and apo E ITS. There was a significant correlation (P < 0·001) between apo E index and apo E ITS. Apo B was detected in all CSF, but ITS of apo B was not observed in any group.
Increase in serum apo E concentration in MS patients is in agreement with that reported in rats with experimental allergic encephalomyelitis, a model of acute MS. 9 ITS of apo E in healthy subjects is about 2·5 mg/day (the daily CSF production is about 500 mL): about 90% of the CSF apo E is derived from this ITS. In the MS group, the daily production is only 1·2 mg/day, i.e. 50% of that of the controls. As no apo B ITS was observed in any patient groups, apo E may play an important if predominant role in the lipid transport within the CNS. The reduction in CSF apo E may impair myelin repair and may explain the progression in MS patients.
Whether this defect in intrathecal apo E is an active or a passive participant in MS disease remains to be clarified.
